≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Acute drug-induced interstitial lung disorder

EFO Endpoint Browser PheWeb

ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — J70.2#

1 out of 7 registries used, show all original rules.

249

4. Check minimum number of events

None

249

5. Include endpoints

None

249

6. Filter based on genotype QC (FinnGen only)

249

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2095 1174 893
Only index persons 1591 915 676
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.02
Only index persons 0.03 0.03 0.03
Median age at first event (years)
Whole population 71.85 72.84 70.45
Only index persons 70.45 71.25 69.35

-FinnGen-

Key figures

All Female Male
Number of individuals 249 122 127
Unadjusted period prevalence (%) 0.05 0.04 0.06
Median age at first event (years) 67.86 64.71 70.89

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
233
Matched controls
2329
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J70.2
ICD-10 Finland
Acute drug-induced interstitial lung disorders
+∞
323.0
233
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
25.3
48.3
69
38
H02AB06
ATC
prednisolone; systemic
6.4
35.1
183
848
UGC12
NOMESCO Finland
Flexible bronchoscopy
8.7
27.6
64
97
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.8
27.0
123
439
TGC00
NOMESCO Finland
Bronchial lavation
15.4
22.9
38
29
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
5.3
20.2
69
171
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
5.7
20.1
63
141
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
7.9
19.4
46
70
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
6.9
19.3
51
91
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
17.0
19.0
30
20
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
13.5
19.0
33
28
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
18.3
153
823
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.2
16.9
57
137
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
5.2
15.7
52
122
C03CA01
ATC
furosemide; systemic
3.0
14.4
121
611
H02AB02
ATC
dexamethasone; systemic
4.7
13.7
50
129
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
6.8
12.7
32
53
R50.9
ICD-10 Finland
Fever, unspecified
3.9
12.4
56
176
JN4BD
NOMESCO Finland
Extensive body CT
3.9
12.2
55
172
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
31.9
11.8
15
5
A04AA02
ATC
granisetron; systemic, transdermal
5.2
11.8
37
81
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
6.6
11.3
29
49
A03FA01
ATC
metoclopramide; systemic, rectal
3.0
11.3
75
314
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
5.9
11.1
31
59
JN4AD
NOMESCO Finland
Body CT examination
4.3
10.9
42
114
L03AA13
ATC
pegfilgrastim; parenteral
7.0
10.7
26
41
C01BD01
ATC
amiodarone; systemic
8.4
10.7
23
30
D70.82
ICD-10 Finland
Drug-induced neutropenia
17.1
10.5
16
10
TPH04
NOMESCO Finland
Cathetrisation of vein
3.0
10.5
70
290
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
4.3
10.4
39
103
GD1AD
NOMESCO Finland
Thorax CT examination
7.3
10.2
24
36
XW000
NOMESCO Finland
Bone marrow biopsy
6.1
10.0
27
49
J01MA12
ATC
levofloxacin; systemic
2.9
9.9
71
309
R06.0
ICD-10 Finland
Dyspnoea
2.7
9.9
82
389
M04AA01
ATC
allopurinol; systemic
3.1
9.8
59
229
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
6.1
9.7
26
47
L04AD01
ATC
ciclosporin; systemic
22.8
9.5
13
6
ZX120
NOMESCO Finland
Intravenous
4.1
9.4
37
102
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
9.4
104
576
I50.9
ICD-10 Finland
Heart failure, unspecified
3.0
9.3
61
248
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
10.7
9.2
17
17
A02BC02
ATC
pantoprazole; systemic
2.5
9.1
170
1218
L04AA06
ATC
mycophenolic acid; systemic
25.2
9.0
12
5
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
25.2
9.0
12
5
N03AX16
ATC
pregabalin; oral
2.7
8.8
70
322
A07EC01
ATC
sulfasalazine; oral, rectal
3.9
8.8
36
103
L04AA13
ATC
leflunomide; oral
8.8
8.8
18
22
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
8.4
8.5
18
23
TPH07
NOMESCO Finland
Cathetrisation of artery
3.3
8.3
43
149
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.8
8.3
27
62
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
13.7
8.0
13
10
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
3.8
7.7
33
98
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
9.3
7.7
15
17
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
9.3
7.7
15
17
NHQ40
NOMESCO Finland
Amputation of toe
8.1
7.5
16
21
C07AB07
ATC
bisoprolol; oral
2.2
7.5
142
978
A02BC01
ATC
omeprazole; systemic
2.3
7.4
85
466
PD4CG
NOMESCO Finland
Extensive MRI examination of abdominal aortta and vasculature of lower extremities with high intensity magnet
11.4
7.4
13
12
D64.9
ICD-10 Finland
Anaemia, unspecified
3.0
7.4
43
162
N02AA05
ATC
oxycodone; systemic
2.8
7.4
51
212
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.2
7.4
27
70
J70.3
ICD-10 Finland
Chronic drug-induced interstitial lung disorders
+∞
7.3
7
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
16.4
7.3
11
7
I50.0
ICD-10 Finland
Congestive heart failure
3.4
7.3
35
115
J01MA14
ATC
moxifloxacin; systemic
3.7
7.2
31
93
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
7.0
43
166
L04AA01
ATC
[U] ciclosporin; systemic
14.3
7.0
11
8
J96.0
ICD-10 Finland
Acute respiratory failure
14.3
7.0
11
8
PD4DE
NOMESCO Finland
Lower extremity artery ultrasound examination with Doppler method
8.7
6.9
14
17
P01BA02
ATC
hydroxychloroquine; oral
3.6
6.9
30
91
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
11.4
6.9
12
11
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.2
6.8
86
488
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.6
6.8
54
246
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
8.2
6.7
14
18
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.2
6.6
24
62
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
6.0
6.6
17
30
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
3.9
6.4
25
69
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.2
6.4
32
109
WW500
NOMESCO Finland
Blood transfusion
4.8
6.3
20
45
A04AA55
ATC
palonosetron, combinations; systemic
7.4
6.3
14
20
L04AX01
ATC
azathioprine; systemic
5.6
6.3
17
32
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.7
6.3
26
76
M05
ICD-10 Finland
Seropositive rheumatoid arthritis
27.5
6.3
8
*
XX3DW
NOMESCO Finland
Time consuming IT work
2.9
6.2
39
153
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
4.7
6.2
20
46
WZC30
NOMESCO Finland
Teaching
2.7
6.1
42
175
B01AB10
ATC
tinzaparin; parenteral
3.4
6.1
28
89
H25.1
ICD-10 Finland
Senile nuclear cataract
2.1
6.0
87
518
L03AA14
ATC
lipegfilgrastim; parenteral
7.6
6.0
13
18

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
31
41
8.49
22.61
4.2
2.7
61.7
59.9
%
0.24
31
41
136
625
3.59
22.12
7.5
4.1
—
—
—
0
0
30
40
8.39
21.71
3.5
2.2
4.4
4.8
e9/l
0.35
30
40
26
29
9.89
21.58
2.4
3.4
—
—
—
0
0
138
658
3.46
20.82
10.2
5.0
—
—
—
0
0
61
182
4.11
18.56
4.5
4.1
1.0
1.0
%
0.01
34
62
160
877
3.31
18.40
11.6
5.4
0.6
0.6
%
0.26
155
813
22
25
9.56
17.93
2.9
1.6
88.7
89.9
%
0.35
22
25
55
159
4.16
17.40
4.4
4.1
1.0
0.4
%
1.39
30
40
57
171
4.03
17.12
4.4
4.3
0.2
0.1
%
0.35
33
55
28
46
6.73
16.78
5.5
2.5
2.9
2.4
mmol/l
0.32
20
26
28
46
6.73
16.78
3.6
2.6
16.8
15.4
%
0.60
11
26
55
164
4.02
16.64
4.3
4.3
0.1
0.2
%
0.25
30
48
167
978
3.15
16.39
10.8
5.2
0.6
0.6
e9/l
0.91
159
845
167
984
3.12
16.09
10.9
5.2
0.0
0.0
e9/l
0.62
159
854
170
1013
3.14
16.03
11.1
5.4
0.2
0.2
e9/l
0.60
163
890
56
174
3.86
15.94
1.8
1.4
—
—
—
0
0
168
1004
3.07
15.58
11.4
5.3
1.6
1.9
e9/l
1.63
163
893
26
43
6.63
15.46
4.2
3.0
—
—
—
0
0
51
152
3.96
15.37
4.1
2.9
10.1
10.3
g/l
0.10
46
138
58
191
3.66
15.12
1.7
1.4
—
—
—
0
0
127
664
2.86
14.93
9.3
3.9
7.4
7.4
ph
1.43
55
132
54
176
3.64
14.24
4.7
4.1
—
—
—
0
0
60
210
3.45
14.19
1.7
1.7
—
—
—
0
0
41
112
4.19
13.85
1.2
1.3
—
—
—
0
0
19
25
8.15
13.75
1.4
1.5
—
—
—
0
0
19
25
8.15
13.75
1.4
1.5
—
—
—
0
0
19
25
8.15
13.75
1.4
1.5
—
—
—
0
0
19
25
8.15
13.75
1.4
1.5
—
—
—
0
0
22
35
6.80
13.52
1.5
2.9
—
—
—
0
0
56
197
3.38
13.06
2.5
1.9
363.2
379.0
nmol/l
0.15
56
180
75
315
2.98
12.95
2.4
1.8
—
—
—
0
0
176
1161
2.76
12.14
18.0
8.5
4.5
4.2
e9/l
0.98
170
1016
88
422
2.68
11.67
8.8
5.3
—
—
—
0
0
58
226
3.04
11.31
1.5
1.3
125.7
546.4
titre
2.59
14
56
89
450
2.52
10.40
3.9
3.1
519.6
564.8
mosm/kgh2o
1.25
81
382
141
880
2.39
10.25
24.7
10.4
0.0
0.0
e9/l
0.01
127
731
20
39
5.49
10.01
2.1
1.7
—
—
—
0
0
102
567
2.35
9.51
4.8
3.3
—
—
—
0
0
148
966
2.31
9.40
11.2
5.3
1.2
1.2
mmol/l
0.65
142
867
158
1068
2.31
9.12
11.3
6.0
1.2
1.2
mmol/l
0.60
107
893
88
476
2.31
8.58
4.0
2.7
7.0
4.5
e6/l
0.59
81
417
21
49
4.59
8.58
1.3
1.1
—
—
—
0
0
41
153
3.01
8.50
4.7
3.6
—
—
—
0
0
138
901
2.19
8.43
19.1
9.8
1.2
1.3
inr
0.90
66
258
43
167
2.90
8.30
4.3
2.3
—
—
—
0
0
64
306
2.47
8.20
3.4
2.5
21.6
21.1
%
0.11
54
263
45
183
2.78
7.97
1.6
1.4
—
—
—
0
0
57
263
2.51
7.85
7.7
5.7
1.3
1.0
mmol/l
0.24
44
209
15
28
5.64
7.83
1.3
1.3
—
—
—
0
0
78
418
2.26
7.65
3.7
1.7
1.5
1.3
mg/l
0.19
64
320
11
15
7.63
7.61
1.2
1.0
—
—
—
0
0
101
604
2.13
7.51
5.0
3.4
0.3
0.5
e6/l
0.77
90
462
20
51
4.18
7.31
3.8
4.7
—
—
—
0
0
10
13
7.97
7.17
2.0
1.7
—
—
—
0
0
105
664
2.01
6.51
5.0
3.5
25.5
165.6
e6/l
0.83
91
522
86
511
2.04
6.30
3.5
2.9
5685.2
7904.1
umol/l
0.15
74
422
100
639
1.94
5.89
3.0
2.3
55.3
56.4
u/l
0.10
94
588
14
32
4.58
5.84
1.1
1.1
—
—
—
0
0
18
52
3.65
5.56
2.8
2.4
132.3
123.9
g/l
0.51
12
37
106
706
1.87
5.40
3.9
3.1
2.3
2.4
mmol/l
0.17
96
611
22
76
3.08
5.18
5.5
3.8
60.2
32.0
mg/l
0.64
12
59
22
76
3.08
5.18
5.5
3.8
140.5
158.5
mg/l
0.06
12
59
27
105
2.76
5.17
1.5
1.3
—
—
—
0
0
81
503
1.90
5.06
15.6
6.5
—
—
—
0
0
11
23
4.96
5.06
2.0
1.1
—
—
—
0
0
11
24
4.75
4.83
1.1
1.0
—
—
—
0
0
101
682
1.81
4.79
4.9
3.3
—
—
—
0
0
109
757
1.78
4.68
5.6
4.1
98.2
93.0
e6/l
0.04
96
559
14
39
3.74
4.55
1.4
1.2
—
—
—
0
0
14
39
3.74
4.55
2.1
1.6
—
—
—
0
0
41
206
2.19
4.55
3.3
2.4
71.2
67.8
e9/l
0.24
34
161
41
206
2.19
4.55
5.0
4.1
2.3
2.0
mmol/l
0.20
31
157
11
26
4.38
4.40
1.1
1.0
—
—
—
0
0
15
45
3.48
4.40
1.3
1.3
—
—
—
0
0
156
1225
1.73
4.17
9.4
4.3
6.8
6.8
mmol/l
0.00
146
1153
25
106
2.51
4.06
12.1
7.0
—
—
—
0
0
16
53
3.16
4.04
2.6
1.5
—
—
—
0
0
11
29
3.92
3.84
1.5
1.4
—
—
—
0
0
43
236
1.99
3.78
9.6
6.0
94.0
95.1
%
0.63
43
231
40
214
2.04
3.77
4.8
4.0
—
—
—
0
0
43
238
1.98
3.69
2.2
1.7
—
—
—
0
0
108
790
1.65
3.60
3.5
2.7
205.1
136.0
ug/l
1.20
101
715
186
1567
1.74
3.53
18.0
7.3
79.3
80.6
u/l
0.15
186
1466
11
31
3.67
3.52
1.7
1.5
31.3
33.0
pg
0.55
11
31
14
47
3.10
3.47
2.9
2.5
—
—
—
0
0
80
550
1.67
3.35
5.6
3.8
—
—
—
0
0
29
144
2.15
3.32
1.9
1.5
—
—
—
0
0
28
139
2.14
3.21
4.0
3.2
5.0
5.1
kpa
0.34
28
127
23
105
2.31
3.20
2.4
2.6
4.3
4.3
pmol/l
0.01
18
90
82
573
1.64
3.20
5.7
4.4
0.0
0.0
estimate
0.00
48
200
42
242
1.88
3.20
1.8
1.4
—
—
—
0
0
115
875
1.58
3.15
6.2
4.3
38.7
40.3
ng/l
0.06
95
683
57
363
1.74
3.14
2.5
1.4
3.2
2.7
g/l
0.59
42
206
15
57
2.74
3.02
2.8
2.4
8.2
7.8
kpa
0.45
15
51
27
136
2.11
2.99
4.1
3.3
7.4
7.4
ph
—
9
20
172
1449
1.60
2.96
7.9
4.2
20.2
13.7
mm/h
4.49
162
1316
47
288
1.78
2.95
1.3
1.3
83.5
15.1
u/ml
1.21
13
110
163
1357
1.58
2.94
6.8
4.6
—
—
—
0
0
10
30
3.43
2.94
1.5
1.5
—
—
—
0
0
16
66
2.52
2.77
2.9
2.5
23.9
24.6
mmol/l
0.37
16
55
16
68
2.45
2.61
1.4
1.2
—
—
—
0
0
9
25
3.69
2.60
1.0
1.1
—
—
—
0
0
125
1004
1.49
2.50
5.5
4.2
0.0
0.0
estimate
0.00
52
197
8
22
3.72
2.38
1.5
1.5
—
—
—
0
0
5
8
6.35
2.38
1.2
1.3
—
—
—
0
0
123
993
1.47
2.35
6.8
5.6
0.0
0.0
estimate
0.00
50
209
122
984
1.47
2.34
5.5
4.1
0.0
0.0
estimate
0.00
54
211
19
93
2.13
2.28
1.5
1.2
1142.8
230.3
u/ml
0.61
19
83
30
176
1.80
2.18
3.3
3.1
4.7
4.2
kpa
0.77
30
168
19
96
2.06
2.12
3.8
4.0
—
—
—
0
0
5
10
5.08
2.08
1.4
1.9
—
—
—
0
0
5
10
5.08
2.08
2.4
2.2
—
—
—
0
0
160
1381
1.44
2.03
6.5
4.4
—
—
—
0
0
63
458
1.50
1.98
1.5
1.3
—
—
—
0
0
54
380
1.54
1.98
6.4
3.7
1012.4
140.5
ng/l
0.57
49
320
31
190
1.72
1.96
11.9
7.1
—
—
—
0
0
8
27
3.03
1.95
1.6
1.3
—
—
—
0
0
6
16
3.81
1.94
1.8
1.1
—
—
—
0
0
11
46
2.46
1.88
5.5
2.5
—
—
—
0
0
11
46
2.46
1.88
1.5
2.8
—
—
—
0
0
6
17
3.59
1.85
1.2
1.2
—
—
—
0
0
5
12
4.23
1.83
1.0
1.0
—
—
—
0
0
5
12
4.23
1.83
1.0
1.0
—
—
—
0
0
5
13
3.90
1.72
1.4
1.2
—
—
—
0
0
62
467
1.44
1.62
2.2
1.8
492.5
443.1
pmol/l
0.87
50
379
6
20
3.05
1.59
2.2
1.1
—
—
—
0
0
44
312
1.50
1.56
1.4
1.3
62.4
44.8
iu/ml
0.30
17
102
71
553
1.40
1.54
2.9
2.1
3.6
3.2
mg/l
0.50
65
470
175
1909
0.72
1.53
4.9
5.4
2.6
2.6
mmol/l
0.02
155
1731
11
51
2.21
1.53
1.1
1.4
261.2
305.3
ug/g
—
5
29
170
1862
0.73
1.51
4.4
4.8
4.5
4.5
mmol/l
0.10
154
1704
15
80
1.93
1.48
9.7
2.0
37.0
37.3
g/l
0.06
15
70
10
46
2.22
1.42
1.4
1.3
—
—
—
0
0
56
427
1.40
1.36
4.0
3.0
2.5
2.5
mmol/l
0.99
49
376
160
1433
1.33
1.32
4.7
3.9
15.0
15.0
pmol/l
0.09
138
1257
170
1847
0.75
1.28
4.3
4.8
1.4
1.5
mmol/l
0.82
153
1672
6
25
2.43
1.25
2.3
4.0
—
—
—
0
0
164
1787
0.76
1.23
3.9
4.2
1.3
1.3
mmol/l
0.51
144
1608
5
19
2.66
1.22
1.4
1.1
—
—
—
0
0
174
1879
0.75
1.20
5.1
5.0
6.2
6.1
mmol/l
0.39
150
1696
24
159
1.56
1.17
1.5
1.4
—
—
—
0
0
57
450
1.35
1.13
1.9
1.8
1146.7
1170.5
nmol/l
0.08
43
346
13
74
1.80
1.09
3.1
1.9
101.8
369.4
ug/l
2.03
13
68
176
1621
1.29
1.05
32.4
17.2
37.6
39.4
%
1.32
100
1044
5
23
2.20
0.98
2.6
2.9
—
—
—
0
0
168
1806
0.79
0.98
6.8
6.5
41.8
40.9
mmol/mol
0.57
151
1663
7
36
1.97
0.98
1.7
2.7
57.4
60.4
%
—
7
36
37
279
1.38
0.98
1.2
1.2
—
—
—
0
0
78
660
1.26
0.92
4.4
4.3
—
—
—
0
0
13
202
0.62
0.87
3.6
3.8
—
—
—
0
0
18
121
1.53
0.85
1.2
1.2
—
—
—
0
0
30
224
1.39
0.85
4.6
2.5
6.8
8.7
umol/l
0.54
23
196
11
65
1.72
0.84
1.6
1.3
0.2
0.2
g/l
0.03
11
65
8
48
1.69
0.79
1.1
1.1
—
—
—
0
0
201
1907
1.28
0.79
38.8
16.2
24.5
25.4
mg/l
0.17
192
1539
9
53
1.72
0.76
1.0
1.1
—
—
—
0
0
36
450
0.77
0.74
3.3
3.2
1.0
0.8
ug/l
0.43
24
313
5
25
2.02
0.73
1.0
1.1
—
—
—
0
0
11
69
1.62
0.69
6.9
3.0
—
—
—
0
0
5
27
1.87
0.69
1.2
1.1
—
—
—
0
0
31
242
1.32
0.68
1.6
1.3
—
—
—
0
0
68
782
0.82
0.68
5.4
5.4
2.5
2.9
ug/l
0.26
55
687
5
91
0.54
0.68
1.2
1.5
—
—
—
0
0
88
785
1.19
0.61
2.3
2.3
—
—
—
0
0
0
23
0.00
0.58
0.0
2.6
—
—
—
0
0
73
643
1.19
0.58
3.2
2.4
—
—
—
0
0
8
54
1.50
0.58
1.1
1.1
—
—
—
0
0
6
40
1.51
0.52
4.7
2.4
—
—
—
0
0
30
244
1.26
0.51
2.6
4.2
12.1
59.0
ug/l
0.81
22
209
37
436
0.82
0.48
6.6
4.6
1.0
1.0
kg/l
—
5
62
66
592
1.16
0.42
3.7
3.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
13
97
1.36
0.40
1.2
1.3
—
—
—
0
0
21
169
1.26
0.40
1.7
1.5
—
—
—
0
0
15
115
1.32
0.40
2.7
2.8
1.0
1.0
%
0.27
15
115
0
19
0.00
0.39
0.0
1.0
—
283.7
—
0
10
14
107
1.33
0.38
1.8
3.0
—
—
—
0
0
45
396
1.17
0.37
1.2
1.2
0.6
1.4
u/ml
—
8
108
9
70
1.30
0.37
4.2
2.2
24.2
21.9
s
—
9
63
196
2017
0.87
0.37
38.6
18.9
138.9
139.7
mmol/l
2.82
189
1955
197
2019
0.88
0.30
39.7
19.0
4.0
4.0
mmol/l
0.41
190
1958
10
76
1.33
0.28
3.3
2.0
—
—
—
0
0
48
526
0.89
0.26
1.6
1.6
1.5
1.3
mmol/l
1.05
35
431
198
2023
0.90
0.25
42.3
19.3
91.0
81.8
umol/l
1.42
198
2023
180
1754
1.09
0.23
5.6
4.7
2.1
2.0
mu/l
0.13
158
1550
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
305.3
—
0
10
0
10
0.00
0.21
0.0
16.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
133.2
—
0
12
5
43
1.17
0.21
2.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
73
690
1.08
0.19
4.1
4.0
9.1
10.9
mg/mmol
0.26
45
438
13
110
1.19
0.17
5.3
4.7
—
—
—
0
0
8
71
1.13
0.16
5.1
5.4
—
—
—
0
0
21
189
1.12
0.14
5.1
3.6
—
—
—
0
0
22
240
0.91
0.12
1.6
1.2
—
—
—
0
0
11
96
1.15
0.10
5.4
3.2
—
—
—
0
0
90
877
1.04
0.08
2.1
2.0
90.1
93.4
pmol/l
0.37
47
442
10
112
0.89
0.07
1.2
1.2
—
27.8
—
0
7
9
103
0.87
0.06
1.7
1.2
—
—
—
0
0
14
130
1.08
0.04
6.0
2.9
—
—
—
0
0
67
657
1.03
0.04
2.9
3.2
51.1
158.5
mg/l
0.58
47
430
45
461
0.97
0.03
4.8
4.0
—
—
—
0
0
67
661
1.02
0.02
2.9
3.1
5.8
7.3
mmol/l
3.30
51
542
198
1972
1.02
0.01
33.6
15.2
—
—
—
0
0
12
121
0.99
0.00
2.8
2.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
10.0
—
588.0
—
0
5
0
5
0.00
0.00
0.0
4.6
—
45.4
—
0
5
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
19.8
—
0
6
0
5
0.00
0.00
0.0
15.4
—
992.8
—
0
5
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
1.2
—
0
5
7
72
0.97
0.00
1.4
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
8
85
0.94
0.00
1.3
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
41.7
—
0
6

Mortality – FinRegistry

↥

Association

Association between endpoint ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD and mortality.

Females

Parameter HR [95% CI] p-value
ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD 2.16 [1.79, 2.61] < 0.001
Birth year 0.993 [0.98, 1.0] 0.097

During the follow-up period (1.1.1998 — 31.12.2019), 543 out of 1003 females with ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD died.

Males

Parameter HR [95% CI] p-value
ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD 3.019 [2.39, 3.81] < 0.001
Birth year 0.992 [0.98, 1.0] 0.103

During the follow-up period (1.1.1998 — 31.12.2019), 468 out of 739 males with ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD died.

Mortality risk

Mortality risk for people of age

years, who have ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD.

N-year risk Females Males
1 0.208% 0.651%
5 1.326% 4.207%
10 3.024% 10.044%
15 5.758% 18.972%
20 10.277% 30.484%

Relationships between endpoints

↥

Index endpoint: ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD – Acute drug-induced interstitial lung disorder

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data